A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

R. V. Iaffaioh, A. Tortoriello, G. Facchini, M. Santangelo, G. De Sena, G. Gesue, L. Bucci, G. Scaramellino, E. Anastasio, A. Finizio, B. Antonelli, V. Vallefuoco, G. Mosella, F. Caponigro

Research output: Contribution to journalArticlepeer-review

Abstract

Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.

Original languageEnglish
Pages (from-to)1256-1258
Number of pages3
JournalBritish Journal of Cancer
Volume72
Issue number5
Publication statusPublished - 1995

Keywords

  • Advanced breast cancer
  • Carboplatin
  • Second-line treatment
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer'. Together they form a unique fingerprint.

Cite this